pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

GSK to cut up to 1,200 jobs in Belgium as part of cost-cutting plan

Oct 14, 2026·read at Endpoints ↗LayoffsNegative

GSK said it will make up to 1,217 workers redundant from its facilities in Belgium.

The job reductions are part of a cost-cutting programme that CEO Luke Miels first outlined in July.

The announcement underscores the company's ongoing restructuring efforts and will impact its Belgian operations.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “GSK could cut more than 1,200 jobs in Belgium”

read at Endpoints ↗
79 words · retrieved 40m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 40m agoArrowhead’s brain-targeting RNA drug lowers Alzheimer’s protein in early studyEndpoints
  • 48m agoZealand inks up to $1.3B deal for AI-designed obesity treatmentsEndpoints
  • 17h agoFTC accuses Martin Shkreli of violating lifetime pharma banEndpoints
  • 17h agoNovartis quietly returns a key antibiotic to US marketEndpoints
  • 18h agoVerdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'Endpoints